CGRP Antagonists Piperidine Core Structural Variations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CGRP-antagonists do not effectively address the need for specific structural variations that enhance their pharmacological properties, such as potency and selectivity, which are crucial for therapeutic applications.
Innovation Solution
Development of compounds with specific structural features, including varied substituents and heterocyclic groups, to create a range of CGRP-antagonists that can be physiologically acceptable salts, improving their pharmacological profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CGRP-antagonists are used, then basic therapeutic function is provided, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions (R1-R6) of the piperidine core structure. Each substituent can be independently selected from specific chemical groups to optimize local interactions with the CGRP receptor, thereby enhancing potency and selectivity without requiring complete structural redesign of the molecule.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, ring sizes, and stereochemistry at specific positions of the piperidine scaffold. This allows fine-tuning of pharmacological properties including potency, selectivity, and metabolic stability while maintaining the core pharmacophore structure.
2Reliability
If structural variations are increased to enhance potency and selectivity, then pharmacological properties improve, but compound complexity increases
Solution Approach 1:
The patent achieves universality by designing a multi-functional piperidine core structure that can accommodate various substituent groups at different positions. This core scaffold serves multiple functions: binding to the CGRP receptor, providing structural rigidity, and offering sites for optimizing pharmacokinetic properties, thereby reducing the need for completely different molecular frameworks.
Solution Approach 2:
The patent applies segmentation by dividing the molecule into distinct functional domains: the piperidine core as the pharmacophore, substituent groups R1-R6 for optimizing specific interactions, and optional stereocenters for enhancing selectivity. This modular approach allows independent optimization of each segment while maintaining overall molecular coherence.
Data Source
AI summary
The present invention relates to the CGRP antagonists of general formulawherein A, X, D, E, G, M, Q and R1 to R3 are defined as in claim 1,the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.